Table 2.
Clinical characteristics and effect of capecitabine according to line of treatment
| Total | 1st line | 2nd line | 3rd line | 4th line | ≥ 5th line | |
|---|---|---|---|---|---|---|
| Number of patients, (%) | 162 (100) | 25 (15.4) | 28 (17.3) | 40 (24.7) | 35 (21.6) | 34 (21.0) |
| ER status, N (%) | ||||||
| Positive (1–100%) | 115 (71.0) | 9 (36.0) | 13 (46.4) | 26 (65.0) | 34 (97.1) | 33 (97.1) |
| Negative (0%) | 41 (25.3) | 16 (64.0) | 14 (50.0) | 10 (25.0) | 1 (2.9) | 0 (0.0) |
| Unknown | 6 (3.7) | 0 (0.0) | 1 (3.6) | 4 (10.0) | 0 (0.0) | 1 (2.9) |
| Metastatic site, N (%) | ||||||
| Bone only | 18 (11.1) | 3 (12.0) | 1 (3.6) | 6 (15.0) | 7 (20.0) | 1 (2.9) |
| CNS | 10 (6.2) | 2 (8.0) | 2 (7.1) | 2 (5.0) | 3 (8.6) | 1 (2.9) |
| Visceral | 118 (72.8) | 16 (64.0) | 19 (67.9) | 29 (72.5) | 23 (65.7) | 31 (91.2) |
| Other | 16 (9.9) | 4 (16.0) | 6 (21.4) | 3 (87.5) | 2 (5.7) | 1 (2.9) |
|
Number of cycles (median) (range) |
6.0 (2–45) | 6.0 (2–26) | 6.0 (2–45) | 6.0 (2–43) | 6.0 (2–32) | 6.5 (2–29) |
|
PFS (months), median (range) |
4.3 (0.5–41) | 4.0 (1–18) | 5.4 (1–41) | 4.1 (1–33) | 4.8 (1–35) | 4.1 (1–21) |
| OS (months), median (range) | 14.2 (1.3–79.9) | 9.3 (1.9–79.9) | 11.6 (1.7–58.5) | 17.8 (1.3–56.6) | 15.3 (2.7–49.7) | 16.0 (3.3–46.5) |
ER estrogen receptor, PFS progression-free survival, OS overall survival